Amrita Y. Krishnan, MD, Talks Future Analyses for Teclistamab in R/R Multiple Myeloma

Amrita Y. Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, professor in the Department of Hematology & Hematopoietic Cell Transplantation, and chief of the Division of Multiple Myeloma at City of Hope spoke with CancerNetwork® at the 2022 American Society of Clinical Oncology Annual Meeting about the evolving landscape of treatments for patients with relapsed/refractory multiple myeloma, including teclistamab and other cellular therapy options.

Krishnan investigated the use of teclistamab in comparison with real-world treatment options for patients with triple-class exposed multiple myeloma who have received 3 or more lines of prior therapy. During treatment, the teclistamab cohort saw better progression-free survival (HR, 0.43; 95% CI, 0.32-0.57; P <.0001), time to next treatment (HR, 0.39; 95% CI, 0.28-0.53; P <.0001), and overall survival (HR, 0.73; 95% CI, 0.50-1.07; P = .1084).

Transcript:

There certainly is a big movement toward using real-world cohorts as comparators as we move ahead with newer myeloma therapies. I do see its place and there are certain challenges in terms of patient-level data vs these large databases. Certainly, I see these analyses being done looking at further variables and as the cohorts grow in the real-world database—such as when the CAR T–treated patients are added to these databases in real numbers and more patients treated with new agents [like] belantamab [mafodotin-blmf; Blenrep]—I do see that these analyses will continue in the future.

Acknowledging the limitations of using a real-world database but also recognizing the absence of data to compare against teclistamab—all the teclistamab data that’s been generated so far is phase 1/2—this was an attempt to try and put it into context of how much of an advantage this is for patients with relapsed/refractory myeloma. I would take that as the take-home [message]. Given the caveats and the limitations of this analysis, it does suggest that this is a very promising new agent for patients with myeloma.

Reference

Krishnan AY, Nooka AK, Chari A, et al. Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2022;40(suppl 16):8036. doi: 10.1200/JCO.2022.40.16_suppl.8036